コーパス検索結果 (1語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 alaciclovir 1 g three times daily (high-dose valaciclovir).
2 clovir), and standard-dose valaciclovir with valaciclovir 1 g three times daily (high-dose valaciclov
3 tandard-dose valaciclovir than for high-dose valaciclovir (10 h vs 7 h; p=0.03), but did not differ s
4 aciclovir (20.2; p=0.54), and standard-dose valaciclovir (14.9) versus high-dose valaciclovir (16.5;
5 rd-dose valaciclovir (14.9) versus high-dose valaciclovir (16.5; p=0.34), but did for no medication (
6 ciated with less shedding than standard-dose valaciclovir (198 [4.2%] vs 209 [4.5%]; IRR 0.79, 95% CI
7 tandard-dose valaciclovir than for high-dose valaciclovir (2.5 vs 3.0; p=0.001), but no significant d
8 d not differ significantly for standard-dose valaciclovir (22.6) versus high-dose aciclovir (20.2; p=
10 00 mg twice daily (standard-dose aciclovir), valaciclovir 500 mg daily (standard-dose valaciclovir) w
11 ing regimen received prophylaxis with either valaciclovir 500 mg orally daily or valganciclovir 450 m
12 atients were randomised (1:1) by computer to valaciclovir (8 g daily) or no additional treatment for
16 t differ significantly between standard-dose valaciclovir and high-dose aciclovir (8 h vs 8 h; p=0.23
21 valaciclovir group than in the standard-dose valaciclovir group (164 [3.3%] vs 292 [5.8%]; 0.54, 0.44
23 Shedding was less frequent in the high-dose valaciclovir group than in the standard-dose valaciclovi
25 higher frequency of headaches with high-dose valaciclovir (n=13, 30%) than with other regimens, all r
27 rly versus late treatment with acyclovir and valaciclovir on zoster-associated pain was assessed from
30 treated volunteers with either valacyclovir (valaciclovir) or no antiviral therapy for 1 year and mea
31 e confirmed CMV disease rate was 11.7% among valaciclovir recipients and 17.5% in the pooled acyclovi
35 tion about CMV disease in AIDS patients, and valaciclovir showed activity as both a preemptive and pr
37 (13 h vs 7 h; p=0.01) and for standard-dose valaciclovir than for high-dose valaciclovir (10 h vs 7
38 (3.3 vs 2.9; p=0.02), and for standard-dose valaciclovir than for high-dose valaciclovir (2.5 vs 3.0
40 e gram of valaciclovir once daily, 250 mg of valaciclovir twice daily, or 400 mg of acyclovir twice d
43 nt difference was recorded for standard-dose valaciclovir versus high-dose aciclovir (2.7 vs 2.8; p=0
45 r-associated pain compared with placebo (and valaciclovir was superior to acyclovir in this regard) e
47 ily (high-dose aciclovir), and standard-dose valaciclovir with valaciclovir 1 g three times daily (hi
48 r), valaciclovir 500 mg daily (standard-dose valaciclovir) with aciclovir 800 mg three times daily (h
WebLSDに未収録の専門用語(用法)は "新規対訳" から投稿できます。